Announcements Trials
Browse Landscape

Phase

Phase 2 36Phase 1/2 17Phase 1 14Phase 3 7Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Glioblastoma 8Recurrence 3Astrocytoma 3Gliosarcoma 2Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Pituitary Neoplasms 1Oligodendroglioma 1Non Small Cell Lung Cancer Metastatic 1Melanoma 1Medulloblastoma 1Glioma 1Ependymoma 1Brain Neoplasms 1Advanced Glioblastoma 1

Interventions

Nivolumab 7Ipilimumab 4pembrolizumab 3Interferon alpha-2 3relatlimab 2Drug Therapy 2Dacarbazine 2sargramostim 1salicylhydroxamic acid 1peginterferon alfa-2b 1peginterferon alfa-2a 1molgramostim 1entrectinib 1cyclopropapyrroloindole 1cobimetinib 1atezolizumab 1Vemurafenib 1Triamcinolone Acetonide 1Temozolomide 1Specimen Handling 1Sonazoid 1Ranibizumab 1Propranolol 1Lenalidomide 1Introns 1Immunotherapy 1Imiquimod 1Fatty Acids, Omega-3 1Crizotinib 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Melanoma × Temozolomide × Clear all
NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡